Core Insights - Kenvue, the maker of Tylenol, has faced significant challenges in 2023, including activist investor pressure and negative publicity related to its products [1][5] - The company has experienced a substantial decline in market value, losing approximately $10 billion following controversial statements from the Trump administration regarding Tylenol's safety [5] Group 1: Company Developments - Kenvue's board underwent significant changes, including the ousting of its CEO and CFO, as well as the appointment of directors from activist investor Starboard Value [2] - A strategic review of Kenvue's operations has been initiated, which may involve a potential sale or breakup of the company [2] Group 2: Market Impact - Following the release of claims linking Tylenol to autism, Kenvue's shares dropped by 9% in a single day [3] - The company's market value is now approximately $30 billion, indicating a significant loss of investor confidence due to recent events [5] Group 3: Regulatory and Legal Challenges - The FDA issued a new warning on Tylenol labels, citing potential risks associated with its active ingredient, acetaminophen, during pregnancy [4] - Ongoing legal challenges include appeals related to lawsuits claiming Tylenol caused autism, which have previously been dismissed for lack of scientific evidence [6]